What is the recommended treatment for tularemia?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: December 3, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Treatment of Tularemia

For severe tularemia, streptomycin (15 mg/kg IM every 12 hours) or gentamicin (1.5 mg/kg IV every 8 hours) should be administered for 7-14 days; for mild cases, doxycycline (100 mg twice daily) or tetracycline (500 mg four times daily) is recommended. 1

Treatment Algorithm Based on Disease Severity

Severe Tularemia (Pneumonic, Typhoidal, or Systemically Ill Patients)

First-line therapy:

  • Streptomycin 15 mg/kg IM every 12 hours (maximum 2 g/day) for 7-14 days 1, 2
  • Alternative: Gentamicin 1.5 mg/kg IV every 8 hours (or 3-5 mg/kg/day in divided doses) for 7-14 days 1

The FDA-approved dosing for tularemia specifically indicates 1-2 g of streptomycin daily in divided doses for 7-14 days until the patient is afebrile for 5-7 days 2. Streptomycin remains the gold standard with a 97% cure rate and no relapses in historical data 3. Gentamicin shows an 86% cure rate with a 6% relapse rate, making it an acceptable alternative when streptomycin is unavailable 3.

Important consideration: Patients over 60 years should receive reduced aminoglycoside dosing due to increased toxicity risk 1, 2. Aminoglycoside doses must be adjusted for renal function 1.

Mild to Moderate Tularemia (Ulceroglandular, Glandular Forms)

First-line oral therapy:

  • Doxycycline 100 mg twice daily for 14 days 1, 4, 5
  • Alternative: Tetracycline 500 mg four times daily for 14 days 1

Doxycycline is FDA-approved for tularemia treatment and provides effective coverage against Francisella tularensis 5. However, tetracyclines have an 88% cure rate with a 12% relapse rate, which is higher than aminoglycosides 3. The relapse risk is particularly elevated when treatment duration is less than 7-10 days 1.

Fluoroquinolones as alternative agents:

  • Ciprofloxacin 750 mg twice daily or levofloxacin 500-750 mg daily for 14 days 1, 6
  • Recent evidence suggests fluoroquinolones may be more effective than doxycycline for mild infections, with excellent clinical response and no relapses in reported cases 7, 6
  • All 10 reported cases treated with fluoroquinolones showed favorable outcomes without relapse 6

Pediatric Dosing

Severe disease:

  • Streptomycin 30 mg/kg/day IM in 2 divided doses (maximum 1 g) 1
  • Gentamicin 6 mg/kg/day IV in 3 divided doses 1

Mild disease:

  • Doxycycline dosing: Patients >45 kg receive adult dosing; patients <45 kg receive 2.2 mg/kg twice daily 4
  • Note: Doxycycline should generally be avoided in children <8 years due to tooth discoloration risk, but may be used for life-threatening infections when benefits outweigh risks 4

Critical Diagnostic and Safety Considerations

Laboratory notification is mandatory: Always notify the microbiology laboratory when tularemia is suspected, as F. tularensis poses significant risk for laboratory-acquired infection 1. Serologic testing (agglutination tests or ELISA) is the preferred diagnostic method 1.

Common Pitfalls and Treatment Failures

Beta-lactam antibiotics are ineffective: Ceftriaxone and other beta-lactams have high failure rates despite favorable in vitro susceptibilities and should never be used 1, 3, 7.

Inadequate treatment duration: Treatment courses shorter than 7-10 days, particularly with bacteriostatic agents like tetracyclines, significantly increase relapse rates 1, 3. Many patients require 14 days of therapy, especially when treatment is initiated more than 2-3 weeks after disease onset 7.

Gentamicin treatment failures: Recent pediatric data demonstrates that gentamicin may fail in oropharyngeal tularemia, with successful salvage using streptomycin for 14 days 8. The 7-day gentamicin course may be insufficient, and delayed initiation may affect outcomes in severe cases 3.

Suppurative lymphadenopathy: Approximately 30% of patients develop suppurative lymph nodes requiring surgical drainage or excision in addition to antibiotics, particularly when antibiotic therapy is delayed 7. High rates of treatment failure and relapse occur regardless of antibiotic choice when treatment begins more than 2-3 weeks after symptom onset 7.

Treatment Duration and Monitoring

  • Aminoglycosides: 7-14 days, with treatment continuing until patient is afebrile for 5-7 days 2
  • Tetracyclines/Fluoroquinolones: Minimum 14 days to reduce relapse risk 1, 7
  • Total streptomycin dose should not exceed 120 g over the entire treatment course 2

References

Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

Research

Streptomycin and alternative agents for the treatment of tularemia: review of the literature.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1994

Guideline

Doxycycline Dosage for Skin Infections

Praxis Medical Insights: Practical Summaries of Clinical Guidelines, 2025

Research

Treatment of tularemia with fluoroquinolones: two cases and review.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 1999

Research

Tularemia treatment: experimental and clinical data.

Frontiers in microbiology, 2023

Research

Treatment failure of gentamicin in pediatric patients with oropharyngeal tularemia.

Medical science monitor : international medical journal of experimental and clinical research, 2011

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.